RemeGen Co. Ltd. Class A
688331
Rang in Aktien
#2415
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Aktienkurs
$14.49
Marktkapitalisierung
$8.11B
Veränderung (1 Tag)
2.99%
Veränderung (1 Jahr)
9.18%
Land
CN
Handel RemeGen Co. Ltd. Class A (688331)
Kategorie
Healthcare
P/B-Verhältnis für RemeGen Co. Ltd. Class A (688331)
P/B-Verhältnis zum October 2026 TTM: 6.73
Laut den neuesten Finanzberichten und dem Aktienkurs von RemeGen Co. Ltd. Class A beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 6.73. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 9.58.
P/B-Verlauf für RemeGen Co. Ltd. Class A von 2018 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 6.73 | -17.42% |
| 2024 | 8.15 | -14.93% |
| 2023 | 9.58 | 16.11% |
| 2022 | 8.25 | 42.80% |
| 2021 | 5.78 | 24.56% |
| 2020 | 4.64 | -105.51% |
| 2019 | -84.22 | 114.76% |
| 2018 | -39.22 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | -7.12% |
US
|
|
| 13.2547 | 96.95% |
US
|
|
| 4.208 | -37.47% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -8.14% |
NL
|
